Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). (Q44071979)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). |
scientific article |
Statements
1 reference
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). (English)
1 reference
Geoff Hale
1 reference
Jeanette Lundin
1 reference
Peppy Rebello
1 reference
Eva Kimby
1 reference
Magnus Björkholm
1 reference
Per-Anders Broliden
1 reference
Fredrik Celsing
1 reference
Viktoria Hjalmar
1 reference
Lars Möllgård
1 reference
Håkan Mellstedt
1 reference
Anders Osterborg
1 reference
1 August 2002
1 reference
1 reference
100
1 reference
3
1 reference
768-773
1 reference
Identifiers
1 reference
1 reference